Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 study of bremelanotide co-formulated with a PDE5 inhibitor (PDE5i), for patients with erectile dysfunction (ED) who do not respond to PDE5i monotherapy

Next Previous
Search
Trial Profile

A phase 3 study of bremelanotide co-formulated with a PDE5 inhibitor (PDE5i), for patients with erectile dysfunction (ED) who do not respond to PDE5i monotherapy

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bremelanotide (Primary)
  • Indications Erectile dysfunction
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 09 Sep 2024 According to Palatin technologies media release, patient recruitment in this Study anticipated in 2H Calendar Year 2025.
  • 30 Jun 2024 New trial record
  • 20 Jun 2024 According to Palatin technologies media release, an IND is expected to be filed with the FDA later this calendar year and a study is expected to start in the first half of calendar year 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top